Stockreport

Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts

Allakos Inc.  (ALLK) 
Last allakos inc. earnings: 11/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.allakos.com/investor-relations
PDF -- 55% (6/11) response rate by UCT in Xolair Refractory CSU patients ---- 49% reduction in UAS7 in Xolair Refractory CSU patients -- -- 77% (10/13) complete hive respon [Read more]